Podcasts about clinical guidance

Link to video: https://www.gochromacreative.com/forestforthetreesAdditional Resources:v Strategies to reduce the stigma of substance use disorderØ Changing language§ https://www.recoveryanswers.org/addiction-ary/ Ø Respectful maternity care§ https://www.awhonn.org/birthequity/ § **Respectful maternity care is an approach that emphasizes treating all women, regardless of their mental health or substance use struggles, with respect, compassion, and encouragement during their pregnancy to improve pregnancy outcomes. v International and national guidelines on managing substance use in pregnant/postpartum womenØ Substance Abuse and Mental HealthServices Administration (SAMHSA)§ https://store.samhsa.gov/product/Clinical-Guidance-for-Treating-Pregnant-and-Parenting-Women-With-Opioid-Use-Disorder-and-Their-Infants/SMA18-5054Ø World Health Organization (WHO)§ https://www.who.int/publications/i/item/9789241548731 v Screening measures for pregnant womenØ Tobacco, Alcohol, PrescriptionMedication, and Other Substance Use (TAPS) Online Screening Tool; https://nida.nih.gov/taps2/§ **Recommended universal screening (yetto be validated with pregnant patients) to identify problematic use ofnicotine, alcohol, and illegal drugs. This is a user-friendlycomputer-administered test that patients can complete on their own or aclinician can administer. It takes about 1 to 8 minutes to complete, dependingon which substances are endorsed. Responses are immediately scored, risk levelsare calculated, and detailed resources and recommendations for treatment areoffered for each substance use problem that is indicated. § **Recommended universal screening forall pregnant patients to identify who may be at risk of and need furtherassessment of alcohol and drug use. This is a 5-question paper and pencilscreener that asks about substance use (in general, not broken down bysubstance type) by a woman's parents, peers, partner, as well as in her pastand currently during pregnancy. It takes about 1 minute to complete, althoughpositive responses will require additional assessments. Ø Adverse Childhood Experiences (ACES)§ **Paper and pencil questionnaire (that could be made into an online survey to facilitate completion), which patients can complete on their own or can be administered by a clinician. Higher ACE scores indicate higher risk for physical and mental health problems, substance use, and other poor outcomes during pregnancy, and referrals to mental health services should

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, epilepsy expert Depobam Samanta, MD, MS, FAAP, FAES, sat down to discuss a recently published guidance paper from members of the Pediatric Epilepsy Research Consortium that provides recommendations for neuromodulation approaches to treat Lennox-Gastaut syndrome (LGS). Samanta, medical director of the Arkansas Children's Comprehensive Epilepsy Program, gave a clinical overview of the paper, highlighting the various neuromodulatory devices and their use, and the ways to improve treatment selection and personalization. Additionally, he talked about some of the potential complications with these devices as well as initiation and titration strategies for easy initiation. Furthermore, he spoke about ways to take neuromodulation to the next level, giving insight on creative trial designs, overcoming sham-controlled studies, and the necessary research to expand these approaches.  Looking for more epilepsy discussion? Check out the NeurologyLive® Epilepsy clinical focus page. Episode Breakdown: 1:05 – Overview of the published guidance and reasons behind the paper  5:15 – Patient selection for neuromodulation and tailoring treatments by patient and preference 8:25 – Overcoming complications with neuromodulation devices  11:25 – Multidisciplinary team necessary for successful implementation of neuromodulation 13:15 – Neurology News Minute 15:15 – Initiation and titration strategies for vagus nerve stimulation, deep brain stimulation, and resective surgery 18:30 – Next steps in research and expanding neuromodulation for patients with LGS 21:10 – Finding creative trial designs to test neuromodulation devices, combination approaches The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Accepts BLA for Subcutaneous Autoinjector Formulation of Lecanemab Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease Real-World Study Highlights Positive Treatment Benefits of Tofersen on ALS Disease Progression, Function Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Human trafficking is a complex health issue, with many providers unsure how best to detect, counsel, and care for victims and survivors of human trafficking. In this episode of the BackTable OBGYN Podcast, hosts Dr. Amy Park and Dr. Mark Hoffman are joined by Dr. Julia Geynisman-Tan, a urogynecologist at Northwestern, to discuss signs of human trafficking and resources for caring for this patient population. --- SYNPOSIS Dr. Geynisman-Tan shares her extensive experience in caring for survivors of human trafficking and discusses the complexities surrounding this issue. She emphasizes the importance of trauma-informed care, recognizing signs of trafficking, and providing support to survivors. The conversation covers her journey into this field, the challenges faced by survivors, and practical steps that healthcare professionals can take to aid these vulnerable patients. The episode underscores the need for multidisciplinary approaches and the critical role of healthcare providers in identifying and assisting those affected by human trafficking. --- TIMESTAMPS 00:00 - Introduction 05:08 - Identifying Signs of Human Trafficking in Patients 09:14 - Referral and Support Systems for Trafficking Survivors 11:31 - Common Health Issues Among Trafficking Survivors 13:17 - Understanding the Complexities of ‘The Life' 18:13 - Immigration and Human Trafficking 20:48 - Providing Trauma-Informed Care 25:55 - Identifying Resources for Victims 29:23 - Healthcare Protocols 32:50 - Addressing Needs and Building Trust 36:58 - Psychosomatic Effects of Trauma 40:50 - Impact on Pregnancy 42:55 - Supporting Survivors and Long-Term Rehabilitation 48:30 - Conclusions --- RESOURCES Human Trafficking Hotline: https://humantraffickinghotline.org/en HEAL Trafficking: https://healtrafficking.org/

Is it too hot outside? What is the CDC doing for climate change? How bad is air pollution right now? What is particle pollution? Is milk safe to drink? Our guest is AMA Vice President of Science, Medicine and Public Health Andrea Garcia, JD, MPH. American Medical Association CXO Todd Unger hosts.

David W. Goodman, M.D., discusses the emerging research on ADHD after age 50, including the disorder's possible association with dementia, the diagnostic process, and safe treatment options for older adults. ADHD in Older Adults: More Resources Download: What Your Doctor Needs to Know About ADHD in Older Adults Read: “I Feared I Had Alzheimer's. It Turns Out It Was Undiagnosed ADHD.” Read: First-Ever Adult ADHD Guidelines Forthcoming Replay: The Science Behind Diagnosing and Treating ADHD in Older Adults, with Dr. David Goodman Access the video and slides for podcast episode #499 here: https://www.additudemag.com/webinar/adhd-in-adults-symptoms-after-50/ Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.

The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years,... The post MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches appeared first on VJHemOnc.

Dr. Esther Chon, author of "Genomic tumor analysis provides clinical guidance for the management of diagnostically challenging cancers in dogs in: Journal of the American Veterinary Medical Association - Ahead of print (avma.org)," discusses how an evidence-driven genomic assay provided diagnostic guidance, prognostic support, and therapeutic options for patients with an unclear cancer diagnosis. Hosted by Associate Editor Dr. Sarah Wright and Editor-in-Chief Dr. Lisa Fortier.INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA OR AJVR?JAVMA: https://avma.org/JAVMAAuthorsAJVR: https://avma.org/AJVRAuthorsFOLLOW US:JAVMA:Facebook: Journal of the American Veterinary Medical Association - JAVMA | FacebookInstagram: JAVMA (@avma_javma) • Instagram photos and videosTwitter: JAVMA (@AVMAJAVMA) / Twitter AJVR: Facebook: American Journal of Veterinary Research - AJVR | FacebookInstagram: AJVR (@ajvroa) • Instagram photos and videosTwitter: AJVR (@AJVROA) / TwitterJAVMA and AJVR LinkedIn: https://linkedin.com/company/avma-journals#VeterinaryVertexPodcast #JAVMA #AJVRINTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

Episode 27 - December 2022 Topic: Flu Vaccination: Navigating Clinical Guidance and Addressing Hesitancy Host: James Millward, DMSc, PA-C Guests: Felicia Gutierrez, PA-C; Sarah McQueen, DMS, PA-C; Justin Wolfe MHS, PA-C Resources: AAPA/PA Foundation animated video - "Flu Vaccine: The More You Know" "In the Words of PAs" blog post - "Flu Vaccination: Using the Health Belief Model to Increase Vaccine Uptake" JAAPA: October 2022 - "Using the Health Belief Model to improve influenza vaccination rates" CDC - Influenza (Flu) CDC - Key Facts About Influenza (Flu) CDC - Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022–23 Influenza Season CDC - Adjuvanted Flu Vaccine AAPA/PA Foundation animated video - "Flu Vaccine: The More You Know" Sanofi - Flu Shot Importance Flash Card Sanofi - Myth Busters Flash Card

Today I chat to Shelley Clarke, who is a Parent Mentor & Educator. Shelley works supporting parents to understand their child's behaviour, and develop rich long lasting relationships. She is a Physiotherapist, CranioSacral Therapist, and a certified Aware Parenting, Hand in Hand Parenting, and Marion Method Mentor. She is passionate about the Nervous System, Human Body and Helping Families Thrive. Shelley is the Host of the "Mind Body Parenting Podcast" - check it out asap. Shelley is a mother to three beautiful children and she is on a mission to shift the paradigm that we parent from. What we cover in the Episode: - Shelley's Origin story of how she got to be a Parent Mentor & Educator. - Her big Beautiful Vision for her Community and the World. - Her top 3 Personal Values currently - Authentic recounts of realistic moments in Parenting and Life when Anger or Rage has been suppressed or not modelled how to express - How to Resource yourself in moments of high or low or mixed Nervous System States via Expression, Play, Resourcing. - A detailed description of Cranio-Sacral Therapy work and how it helped to Transform moments of Shelley's Life. - What is Attachment Play or PlayListening? - Shelly and I do a little Playful skit as an example of using Play to reconnect and find Balance again for children and Care Providers. We laugh and giggle our way through this. Thank you Shelley for our chats both on and off air (we spoke for a while after this recording too) - I'm already looking forward to chatting to you again. xx Abbey You can find Shelley on her website www.shelleyclarke.com Instagram: _shelleyclarke_ Facebook: @shelleyclarkemindbodyparenting Podcast: Mind Body Parenting Podcast (on all of the Podcast Platforms) If you're looking for Coaching for your Life, Family, Season or Business - connect with Abbey for Somatic Bloom 1:1 Coaching Online via Zoom. https://www.paypal.com/instantcommerce/checkout/JBKGVPHATM96U If you're Interested in a Somatic Immersion Online Women's Circle the next date is October 16th - and here is the link https://www.paypal.com/instantcommerce/checkout/SMLTJH6TE7WB8 Other helpful links: http://awareparenting.com/ https://www.handinhandparenting.org/ https://www.somaticexperiencing.com/ Somatic Experiencing Australia http://www.seaustralia.com.au/ **This podcast is not a medical or Clinical Podcast - this is a Coaching Space only. If you require or seek Medical or Clinical Guidance please seek alternative help and support via your General Practitioner.**

This episode is sponsored by HelloFresh! Save 65% and get FREE shipping when you use code LifeAfterMLM65! *Content Warning - this episode mentions about trauma, mental health, miscarriage, and disordered eating. Please use discretion when listening.* Jeanette was a Diamond Coach during her 5 year stint in Beachbody, running the MLM rat race with undiagnosed ADHD, chasing the dopamine fueled high of being a top BossBabe. I also struggled with undiagnosed ADHD while in MLM, chasing the same fix and so I wondered, Is there a connection between MLM and Neurodivergency? Jeanette and I talk about the similarities between our journeys with ADHD, how MLMs and social media played a part, and what healthy boundaries and personal privacy in a digital space looks like. Show Notes Follow Jeanette on IG - https://www.instagram.com/with_love_jeannette/ Follow Jeanette on TikTok!- https://www.tiktok.com/@anti_mlm_jeannette Childhood Trauma and ADHD: A Complete Overview & Clinical Guidance - https://www.additudemag.com/adhd-and-trauma-overview-signs-symptoms/ What is Rejection Sensitivity Dysphoria? - https://www.psychologytoday.com/us/blog/friendship-20/201907/what-is-rejection-sensitive-dysphoria Briannah Jewel - https://www.youtube.com/channel/UCV_WEuCC_OwOH-FTAwNbWEg Carl Daikeler refers to Beachbody Coaches as “unsophisticated” on quarterly earnings call - https://www.youtube.com/watch?v=Y5CjL1grxPs Cultish by Amanda Montell - https://amzn.to/3Q7owx9 Dr. Steven Hassan's BITE Model - https://freedomofmind.com/cult-mind-control/bite-model/ Ponzinomics by Robert L. FitzPatrick - https://amzn.to/3q16oJb How can you help? Report false income and health claims here: https://reportfraud.ftc.gov/ Or go to: https://www.truthinadvertising.org You can also report to your state Attorney General's office! https://www.naag.org/find-my-ag/ Not in the U.S.? Go here: https://www.ftc.gov/policy/international/competition-consumer-protection-authorities-worldwide Support the Podcast! Join the Patreon! - https://www.patreon.com/robertablevins Buy me a Taco and leave a note!

So many women are grossed out by their bleed. We spend as much time as possible during our menstrual phase trying to disguise the fact that we are bleeding. We go to great lengths! While you might be trying hard to hide your bleed from everyone else, on todays episode Cody talks to us about how important it is to not hide it from ourselves. She teaches us that how paying attention to the color, flow and the consistency can give us some of the greatest insights into our overall health. Tune into this episode to learn more about how to decode your period blood, and learn about the five period blood types. Knowing this information allows us to “course correct” every month to support optimal hormone balance and overall wellness. Study cited:https://acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Menstruation-in-Girls-and-Adolescents-Using-the-Menstrual-Cycle-as-a-Vital-Sign?!IsMWant to join our Mixhers Girl community and keep this conversation going? We'd love to hear your thoughts, feelings and experiences! Join us HERE!Did you learn something new today? Be sure to subscribe to this podcast and share this episode with all the girls you love. We would appreciate it if you'd also rate us and leave a comment on iTunes.Join Mixhers email list and be the first to have access to new products and be the girl in the know! Be sure to join our movement by following us on Instagram @mixhersorCody Sanders @codyjeansandersJess Toolson @jesstoolsonTo submit questions or if you think you'd be a perfect guest to have on our podcast reach out to us on speakpipe and record your questions for us!You can also contact mccall@mixhers.com or DM McCall @mixhers on IG.Today's show is sponsored by Mixhers

The Filtrate:Joel TopfNayan AroraSophia AmbrusoSwapnil HiremathJosh WaitzmanSpecial Guest:Natalie Bello Director of Hypertension Research at Cedars SinaiEditor:Nayan AroraShow Notes:NephJC summary of CHAPCHiPS TV showCHIPS study: Less-Tight versus Tight Control of Hypertension in PregnancyPrevention, Diagnosis, and Management of Hypertensive Disorders of Pregnancy: a Comparison of International Guidelines (Pubmed)SFLT in preeclampsia from where else but NephMadness and here.Aspirin Use to Prevent Preeclampsia and Related Morbidity and MortalityUS Preventive Services Task Force Recommendation Statement (JAMA)The NNT for aspirin in pregnancy is like a relationship on Facebook, it's complicated. Astrologic signs as predictor of aspirin effectiveness in Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (Pubmed) ACOG revises the guidelines on hypertension: Clinical Guidance for the Integration of the Findings of the Chronic Hypertension and Pregnancy (CHAP) StudyMeta-analysis showing treating blood pressure in pregnancy didn't help. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.

Heather and Maureen interview Kelly Lemon, APRN, CNM, WHNP.  Together they tackle Opioid Use Disorder and the impacts that this disorder can have on breastfeeding relationships. This is a shame-free zone...come dig into the research on the opioid crisis and gain the best, evidence based healthcare information! Don't miss this episode!THANK YOU TO THIS EPISODE'S SPONSORSClick HERE and use promo code MILKMINUTE to get your Uberlube!Get your breastfeeding journey BACK ON TRACK with a Lactation Consult with Heather! Telehealth available and some insurance accepted. Click the link below for the deets.Click here to Work with HeatherWe've got two listener questions this week! 1. A school-based occupational therapist says that she's seeing an increase in students with difficulties that she thinks may be linked to the opioid crisis; what do you recommend for the babies once they're discharged from you?2. Have you seen an uptick in opioid use since the start of the pandemic, and if you're a new user, where should you go for help?Find the new Milk Minute Podcast website by clicking here!Become a Milk Minute VIP: Click here to get behind-the-scenes-access and exclusive merch!Contact us: To send us feedback, personal stories, or just to chat you can send us an email at milkminutepodcast@gmail.comGet Community Support: Click Here to Join our Free Facebook Community!Stay up to Date: Find us on INSTAGRAM @milk_minute_podcastPrefer to read the transcript?- Click Here to read the edited version of this episode!Resources:Kelly Lemon, APRN, CNM, WHNP https://directory.hsc.wvu.edu/Profile/47979https://wvumedicine.org/find-a-doctor/doctor-details/?id=1749Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infantshttps://store.samhsa.gov/product/Clinical-Guidance-for-Treating-Pregnant-and-Parenting-Women-With-Opioid-Use-Disorder-and-Their-Infants/SMA18-5054https://store.samhsa.gov/sites/default/files/d7/priv/sma18-5054.pdfFindTreatment.govSupport the show (https://www.patreon.com/milkminutepodcast)

For better or worse, Allan and Rob are reunited as they rehash some of the early COVID-19 literature and scientific direction for ED and critical care nurses.

Fortifying the Treatment of Prostate Cancer With AR-Targeted Therapy: Solidifying Clinical Guidance With Practical Evidence

The COVID-19 Clinical Guidance series of podcasts is a collaboration with leading experts in cardiovascular, critical care and stroke medicine to disseminate the most up-to-date information for our healthcare providers on the frontline of patient care delivery. This episode focuses on the issues surrounding vulnerable populations as they relate to COVID-19 and the coronavirus pandemic overall.

Do you want to know how to take precautions as a mom amidst the coronavirus? Dr. Farah explains what coronavirus is, why it is different than the flu, tips on how to take precautions (which is different than panicking!) and what pregnant women need to know. She also puts things into perspective to give some positivity and hope to the situation. Links mentioned in episode: https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Novel-Coronavirus2019?IsMobileSet=false https://www.bbc.com/news/uk-51917562 DISCLAIMER: THIS EPISODE IS NOT MEDICAL OR LEGAL ADVICE AND PRESENTED FOR INFORMATIONAL PURPOSES ONLY.  THE STATEMENTS ON SACRED BLOSSOM TEA HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION.  THE TEA IS NOT INTENDED TO DIAGNOSE, TREAT, CURE OR PREVENT DISEASE.

https://www.ncbi.nlm.nih.gov/pubmed/30347032  Terbinafine adverse effects are rare https://www.ncbi.nlm.nih.gov/pubmed/31189511 Dulaglutide prevents MACE but at a high price tag https://www.ncbi.nlm.nih.gov/pubmed/30853124   If you punch your buddy then get some buddy tape https://www.ncbi.nlm.nih.gov/pubmed/31076416 prediabetes gibes me a headache    https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Access-to-Hormonal-Contraception    Over the counter birthcontrol!! 

This week we sit down with our very own expert, Vanessa. She is a certified nurse-midwife, nurse practitioner, doula, mother extraordinaire! We chat all things pap smear -- the who, what, where, when, and why. This highly requested episode provides accessible information on pap smears to women of all ages. As always, we have our weekly sex check-in with Denae and banter about our recent happenings. In this episode we talk about: - HPV Facts: https://www.cdc.gov/std/hpv/stdfact-hpv.htm - American Cancer Society Breast Cancer Screening Guideline: https://www.cancer.org/latest-news/special-coverage/american-cancer-society-breast-cancer-screening-guidelines.html - Cervical Cancer Screening Guidelines: https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Cervical-Cancer-Screening-Update?IsMobileSet=false - Abnormal Pap Smear Results: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/D518183F0E9F8176CA257D7100098ABA/$File/pap-smear.pdf Subscribe today on any podcast listening app and leave a rating and review to let us know what you think! Your feedback makes our day. Connect with us on Facebook, Instagram, and Twitter! If email is your thing, send us a note at hello@atyourcervix.us Just a reminder, the purpose of this podcast is to educate and empower, it is no substitute for professional care by a doctor or other qualified medical professional. Guests who speak in this podcast express their own opinions, experience, and conclusions. If you have any specific questions about any medical matter, you should consult your doctor or another professional healthcare provider.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Go online to PeerView.com/GQC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel therapeutic drug classes have transformed the management of several B-cell lymphoma subtypes, including chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma. The arrival of BTK and PI3K inhibitors, next-generation antibodies, immunomodulators, BCL-2 inhibitors, CAR T cell therapy, and other strategies provides an opportunity to formulate more personalized management approaches to improve patient outcomes in many different B-cell non-Hodgkin lymphoma settings. Integrating these novel agents with current treatment paradigms entails moving away from a chemotherapy-centric approach and developing tailored strategies guided by patient or prognostic features, as well as the most recent clinical evidence. Upon completion of this activity, participants should be better able to: Cite patient, disease, and molecular/cytogenic factors that can guide the use of novel therapeutic classes in the management of B-cell cancers, Describe updated evidence on the use of BTK, PI3K, and BCL-2 inhibitors; immunomodulatory drugs; CAR T cell therapy; and novel antibodies in the management of indolent and aggressive B-cell cancers, Select regimens with novel components for the management of newly diagnosed or relapsed/refractory B-cell cancers, Manage treatment-emergent safety considerations in patients with B-cell cancers who are receiving therapy with novel agent classes.

Dr. Bergoy walks us through the risks and benefits of elective cesarean delivery. www.obgyn.fm feedback@obgyn.fm neonatal and maternal mortality https://www.acog.org/Clinical-Guidance-and-Publications/Obstetric-Care-Consensus-Series/Safe-Prevention-of-the-Primary-Cesarean-Delivery https://www.ncbi.nlm.nih.gov/pubmed/?term=24631705%5Buid%5D https://www.uptodate.com/contents/cesarean-delivery-on-maternal-request?search=cesarean%20section%20complications&source=search_result&selectedTitle=6~150&usage_type=default&display_rank=6#H16 Primary cs vs trial of labor Visco et al’s review https://www.ncbi.nlm.nih.gov/pubmed/?term=visco+cesarean+delivery+on+maternal+request+obstetrics+and+gynecology+2006 Declercq et al’s study https://www.ncbi.nlm.nih.gov/pubmed/?term=Declercq+et+al%2C+green+journal%2C+109(3)%2C+2007+%C2%ABMaternal+Outcomes+Associated+With+Planned+Primary+Cesarean+Births+Compared+With+Planned+Vaginal+Births%C2%BB Allen et al https://www.ncbi.nlm.nih.gov/pubmed/16880297 Liu et al, AJOG, vol 212 issue 6 2015. “Cesarean delivery on maternal request in China: what are the risks and benefits?” https://www.ncbi.nlm.nih.gov/pubmed/?term=25640048 Liu et al, CMAJ, vol 176, issue 4 2007 “Maternal mortality and severe morbidity associated with low-risk planned cesarean delivery versus planned vaginal delivery at term” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800583/ TOLAC vs secondary elective cesarean Guise et al, Obstet gynecol, june 2010 vol 115, no 6, “Vaginal birth after cesarean: new insights on maternal and neonatal outcomes.” https://www.ncbi.nlm.nih.gov/pubmed/?term=20502300 Crowther et al, PLoS med, 2012, 9(3). «Planned Vaginal Birth or Elective Repeat Caesarean: Patient Preference Restricted Cohort with Nested Randomised Trial« RDS Hansen et al BMJ 2008 “Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study” https://www.bmj.com/content/336/7635/85 Long term complications Marshall et al «Impact of multiple cesarean deliveries on maternal morbidity: a systematic review» Am J Obstet Gynecol2011;205:262.e1-8. https://www.ncbi.nlm.nih.gov/pubmed/22071057 Keag et al systematic review and metaanalysis of long term risks and benefits of cs vs vag delivery for mother and child from jan 18 in PLoS med https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002494 editorial in the green journal from 2011 on the evidence of CS as protective of pelvic floor damage https://www.ncbi.nlm.nih.gov/pubmed/21934440 composite outcomes Freemantle et al Jama 2003 https://jamanetwork.com/journals/jama/fullarticle/196588 Cordoba et al BMJ 2010 https://www.bmj.com/content/341/bmj.c3920 Various An article on how to counsel a patient on risks and benefits woth cesarean on maternal request from Jama 2013 https://jamanetwork.com/journals/jama/fullarticle/1685873 NNT https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524406/

The Scientific American magazine has just released its newest issue (May 2019) and one of the articles featured asks the question, what is the point of our periods? You would think that females have had periods now for hundreds of years and we would have a greater understanding of the reason why we bleed and the purpose of our menstrual blood, but research is not much closer to this answer as we are to knowing something that we do every month. But what if you are on some type of birth control and you don't bleed based on your natural hormones or you medically suppress your bleeding indefinitely, what consequences are there for changing around the make-up of our reproductive system? I provide a brief synopsis on certain points made in the article and provide some reflection on how we view our own periods. The link to the Scientific American article: https://www.scientificamerican.com/article/what-is-the-point-of-a-period/ The link to the 2015 ACOG Opinion on menstrual cycles as a vital sign: https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Menstruation-in-Girls-and-Adolescents-Using-the-Menstrual-Cycle-as-a-Vital-Sign --- Support this podcast: https://anchor.fm/themasterfulartofselfcare/support

Buckle up for a thorough discussion about cervical exams, kweens! Here’s what you’ll hear about in this episode: What is a cervical exam and how are they performed What’s being assessed in a cervical exam (i.e. dilation, effacement, station, cervical ripeness and position, etc.) How to do a respectful cervical exam Tips for how to make exams more comfortable for the person receiving them Cervical exams during pregnancy – why they’re done and whether they’re actually necessary The role that cervical exams play in inductions of labor and why it’s important to know your Bishop’s Score before starting an induction Definition of a membrane sweep (aka – stretch and sweep) The lowdown on cervical exams during labor, including the risks and benefits The normal frequencies of cervical exams in labor in a hospital vs. birth center/home birth Discussion about the recent change in definition of the start of active labor from 4cm to 6cm https://www.acog.org/Clinical-Guidance-and-Publications/Obstetric-Care-Consensus-Series/Safe-Prevention-of-the-Primary-Cesarean-Delivery https://evidencebasedbirth.com/friedmans-curve-and-failure-to-progress-a-leading-cause-of-unplanned-c-sections/ https://www.ajog.org/article/S0002-9378(13)01690-6/abstract Some myths about cervical exams and dilation in labor The resources mentioned about the uterine infection chorioamnionitis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008318/ https://www.ncbi.nlm.nih.gov/pubmed/22432485 https://www.ncbi.nlm.nih.gov/pubmed/22617572 The pros and cons of the birthing person knowing the numbers associated with their cervical exams in labor Discussion about how labor progress and cervical dilation are not always linear   Support our sponsor and get your own subscription to Ritual vitamins by going to Ritual.com/KWEENS.   Get yourself some Birth Kweens gear in our new online shop! --- If you liked this episode of the Birth Kweens Podcast, tell your friends! And go to iTunes, Stitcher, GooglePlay, and Spotify to rate/review/subscribe to the show. For more from us, visit www.BirthKweens.com to sign up for our newsletter. Follow us on Instagram @BirthKweens, join our Facebook group the Birth Kweens Podcast Community, and email us at birthkweens@gmail.com with your questions, suggestions and feedback. Also, be sure to click here so that you can support the show while doing your regular Amazon shopping!

Pregnancy complications make us all a little diaphoretic and tachycardic. On this episode, Dr. Patrick and Dr. Dickson break down the must know aspects of caring for the obstetric patient prior to delivery in the EMS setting. References: https://www.acog.org/Clinical-Guidance-and-Publications/Task-Force-and-Work-Group-Reports/Hypertension-in-Pregnancy

Avin KG, Hanke TA, Kirk-sanchez N, et al. Management of falls in community-dwelling older adults: clinical guidance statement from the Academy of Geriatric Physical Therapy of the American Physical Therapy Association. Phys Ther. 2015;95(6):815-34. CDC’s STEADI Tool Kit   ------------ This episode is sponsored by the Academy of Geriatric Physical Therapy. Check out one of their MOST POPULAR papers from Dale Avers - White Paper: Strength Training for Older Adults. Get this resource (& much more!) at http://GeriatricsPT.org/SRP ------------ SRP is brought to you by the generous support of the SRP Game Changers. If you want to Join SRP, Crush Mediocrity, Join the Monthly Meetups, & Get some free swag!... go to http://SeniorRehabProject.com/Join

Hi everyone, Thanks for joining us again, this week I am joined by my colleague Prof Yee Leung, Head of Gynaecological Oncology in Western Australia, to discuss the obstetric and surgical aspects of managing the patient with an abnormally invasive placenta (accreta / increta / percreta). Please join us, listen to our conversation on the podcast and let us know if you have any comments or questions. Definitions: Accreta = the chorionic villi are in contact with the myometrium (78%) Increta =  the chorionic villi invade the myometrium. (17%) Percreta = the chorionic villi penetrate the uterine serosa. (5%) Risk factors: Previous caesarean delivery: The authors of one study found that in the presence of a placenta previa, the risk of placenta accreta was 3%, 11%, 40%, 61%, and 67% for the first, second, third, fourth, and fifth or greater repeat cesarean deliveries, respectively. Placenta previa (without previous uterine surgery): 1–5% risk of placenta accreta. Any condition resulting in myometrial tissue damage followed by a secondary collagen repair, eg myomectomy, vigorous curettage resulting in Asherman syndrome, submucous leiomyomas, thermal ablation , and uterine artery embolization. ACOG https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Placenta-Accreta RANZCOG https://www.ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women's%20Health/Statement%20and%20guidelines/Clinical-Obstetrics/Placenta-Accreta-(C-Obs-20)-Review-March-2014,-Amended-November-2015.pdf?ext=.pdf Diagnosis - Imaging Modalities: https://radiopaedia.org/articles/placenta-accreta USS or MRI Surgical management Surgical management of placenta accreta: to leave or remove the placenta? A Perez-Delboy, JD Wright 2014 Timing of Delivery Placenta Accreta: When is the optimal time to deliver? Manual Aortic Occlusion Our podcast discussion on this topic Interventional Radiology 3) REBOA during unexpected uterine rupture https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628233/ 2) Comment urging caution before embracing interventional radiology techniques: http://www.obstetanesthesia.com/article/S0959-289X(16)30075-9/pdf Communication and Having an Effective Team Fostering a culture of safety: The OR team huddle Conservative Management Leaving the placenta in situ, Methotrexate, En bloc resection, Hysteroscopic resection